Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location

Huntington's Disease Clinical Trials

A listing of Huntington's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (126) clinical trials

Enroll-HD is a longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to ...

Phase N/A

The aim of this clinical study is to investigate the efficacy and safety of laquinimod as a potential treatment for patients with Huntington’s disease. This study is being conducted to determine if laquinimod helps with the signs and symptoms of Huntington’s disease after 12 months of treatment.

Phase N/A

The Equinox Study is a clinical research study that is evaluating an oral investigational medication to see if it may reduce moderate to severe pain associated with endometriosis. 


Randomized Placebo-controlled Multi-dose Study Comparing Budesonide/Formoterol to Symbicort in Asthmatic Patients

This is a pivotal trial that will examine therapeutic equivalence of a new generic fixed-dose combination product containing Budesonide 80 mcg / Formoterol fumarate dihydrate 4.5 mcg and reference listed drug (RLD) Symbicort inhalation aerosol in adult patients with chronic but stable asthma as defined in National Asthma Education and ...


Tolerability Safety and Activity of SRX246 in Irritable Subjects With Huntington's Disease

SRX246 is a first-in-class vasopressin 1a (V1a) receptor antagonist that crosses the blood-brain barrier following oral administration. The molecule exhibits high affinity and high selectivity for its target receptor. Preclinical pharmacology studies have demonstrated significant CNS effects in models of irritability, including impulsive aggression, depression, and anxiety. In an experimental ...


A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

This study is an open-label assessment of behavioral symptoms including depression, impulsivity, and suicidal ideations in patients prior to, and after, taking a stable dose of TBZ for Huntington's disease. All subjects will be evaluated with tests of depression (Beck Depression Scale), impulsivity (QUIP, BIS-11, and computerized impulsivity scales), and ...


Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IONIS-HTTRx administered intrathecally to adult patients with early manifest Huntington's Disease.


Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...


Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)

In this study the efficacy and safety of pallidal Deep Brain Stimulation (DBS) in HD patients shall be investigated and superiority of DBS on motor function in the stimulation group compared to the stimulation-off group shall be shown. This study is a prospective, randomised, double blind, parallel group, sham-controlled, multi-centre ...

Phase N/A

Micra Transcatheter Pacing System Post-Approval Registry

The Micra Registry is a global, prospective, observational, multi-site registry. Patients enrolled in the Micra Registry will be prospectively followed for a minimum of 9 years post-implant or until registry closure, patient death, patient exit from the registry (i.e., withdrawal of consent), or unless patient is participating in an acute ...

Phase N/A